India drug price cuts expected to hit hard; Sun, Glenmark approved for generic Rilutek; Maine OKs mail-order drug buys;

@FiercePharma: Needy Forest Labs reportedly eyes a bid for Elan. But why? Yesterday's story | Follow @FiercePharma

@EricPFierce: Who manufactures the top selling diabetes treatments? Novo has 5 of top 10, but not the top two. Special report | Follow @EricPFierce

> The U.S. Department of Justice has sued Sage Pharmaceuticals, a Shreveport, LA, company it says has been selling unapproved drugs over-the-counter. Release

> The FDA Thursday approved Abbott's ($ABT) RealTime HCV Genotype II test to identify the genotype of hepatitis C virus (HCV) that patients are carrying, which will help doctors decide what treatment they should receive. Announcement | More from FierceMedicalDevices

> Price cuts on 151 essential drugs in India are expected to have a huge impact on the drug industry there. Report

> India's Sun Pharmaceutical Industries and Glenmark Generics say they have been approved by the FDA to make generic versions of Sanofi ($SNY) myotrophic lateral sclerosis treatment Rilutek. Report

> The Maine legislature has approved a bill to permit citizens to buy prescription drugs from mail-order pharmacies in Canada, the U.K., New Zealand and Australia. Story

Medical Device News

@FierceMedDev: Endo's AMS owes $54.5M in vaginal mesh lawsuit. News | Follow @FierceMedDev

@DamianFierce: Philips' is enduring its third ventilator recall in about a year, drawing a deadly FDA warning. Report | Follow @DamianFierce

@MichaelGFierce: Biosensor nanoparticles deliver cancer drug with precise, 3-D imaging. FierceDrugDelivery story | Follow @MichaelGFierce

> GE pads mammography prowess with Korean buyout. Story

> Abbott wins FDA nod for hep C gene test. Article

> France ponies up for study of GI Dynamics' obesity tech. More

> Medtronic ups dividend, eyes share buyback. Item

Biotech News

@FierceBiotech: ICYMI: 10 startups fueling pharma in social media. Special report | Follow @FierceBiotech

 @JohnCFierce: Under review and well past Ph3: Can Novartis gain anything from its latest breakthrough drug win at the FDA? Article | Follow @JohnCFierce

@RyanMFierce: The news: Ablynx heads to PhI w/ German Merck. The takeaway: Misspell Merck Serono, and it rhymes with 'My Sharona." Story | Follow @RyanMFierce

 @EmilyMFierce: New at FierceBiotechResearch.com: Penn scientists create human-cell model of pancreatic cancer. Story | Follow @EmilyMFierce

> J&J spreads deal-making net with global ring of satellite offices. More

> Takeda asks FDA to OK its potential inflammatory bowel disease blockbuster. News

> Idenix plunges after FDA throws up a roadblock for lead hep C 'nuc.' Report

And Finally... A report says that approval of the anticoagulent Eliquis from Bristol-Myers Squibb ($BMY) and Pfizer ($PFE) was held up for 9 months by trial study issues. Report

Suggested Articles

Even as it gears up for phase 3 testing, Moderna has started commercial COVID-19 vaccine manufacturing, its CEO said.

Fitness guru and heart attack survivor Bob Harper is back again in AstraZeneca’s awareness effort to offer support and education to fellow survivors.

Taxpayers spent nearly $100 million to save remdesivir from the "scrapheap," a lawmaker wrote, and are being repaid with "price gouging."